Navigation Links
Celladon Corporation Announces Oral Presentation at American Heart Association of Long Term Follow-Up Results from the MYDICAR CUPID 1 Trial in Advanced Heart Failure
Date:11/18/2013

l, MYDICAR was found to be safe and well-tolerated, reduced heart failure-related hospitalizations, improved patients' symptoms and quality of life, and improved key markers of cardiac function predictive of survival, such as elevated levels of natriuretic peptides and end systolic volume.  Three dose levels of MYDICAR were administered, and the high-dose MYDICAR group met the primary endpoint versus placebo at six months, and all positive trends were confirmed at 12 months. The hazard ratio at 12 months for the high-dose MYDICAR group versus placebo for recurrent adjudicated clinical events was 0.12 (p=0.003) representing a risk reduction of 88% with MYDICAR versus placebo. No safety concerns were noted.

About Celladon

We are a clinical-stage biotechnology company applying our leadership position in the field of calcium dysregulation by targeting SERCA enzymes to develop novel therapies for diseases with tremendous unmet medical needs. Sarco/endoplasmic reticulum Ca2+-ATPase, or SERCA, enzymes are a family of enzymes that play an integral part in the regulation of intra-cellular calcium in all human cells. Calcium dysregulation is implicated in a number of important and complex medical conditions and diseases, such as heart failure, diabetes and neurodegenerative diseases. Our therapeutic portfolio for diseases characterized by SERCA enzyme deficiency includes both gene therapies and small molecule compounds. MYDICAR, our most advanced product candidate, uses gene therapy to target SERCA2a, which is an enzyme that becomes deficient in patients with heart failure. In a 39-patient randomized, double-blind, placebo-controlled Phase 2a trial in patients with systolic heart failure, which we refer to as CUPID 1, MYDICAR was found to be safe and well-tolerated, reduced heart failure-related hospitalizations, improved patients' symptoms, quality of life and serum biomarkers, and improved key markers of cardiac function predictive of survival, such as
'/>"/>

SOURCE Celladon Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Celladon Corporation Named a 2012 Fierce 15 Company by FierceBiotech
2. Celladon Corporation To Present at BioCentury Future Leaders in the Biotech Industry Conference
3. Celladon Corporation and SIRO Clinpharm Announce Presentation at "Statisticians in the Pharmaceutical Industry International Conference"
4. Celladon Corporation Selected as Winner of Red Herrings "Top 100 North America Tech Startup"
5. Celladon Corporation Announces Pre-clinical Study Demonstrating Inhalable MYDICAR Reverses Pulmonary Arterial Hypertension (PAH)
6. Celladon Corporation Announces Appointment of Gregg Alton and Graham Cooper to its Board of Directors
7. Celladon Corporation Announces Publication of Long Term Follow-Up Results from the MYDICAR CUPID 1 Trial in Advanced Heart Failure
8. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2012 Financial Results
9. Kensey Nash Corporation Announces Achievement of $6 Million Milestone From Spectranetics Corporation
10. China Cord Blood Corporation Announces Results of 2011 Annual General Meeting
11. Neogen Corporation Announces 2nd Quarter Results Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... ... ... Inc. Magazine released its annual list of the 5,000 fastest-growing privately held companies ... three years through 2014. Being named to the Inc. 5000 list designates a company ... , “We are thrilled to make the Inc. 5000 list for 2015,” stated Tad ...
(Date:8/27/2015)... PARK, N.C. , Aug. 27, 2015 /PRNewswire/ ... the decision by FedEx, UPS and The US ... certain biological specimens classified as ,select agents, by ... long history of handling these sensitive shipments. ... of global transportation regulations, trained and certified personnel ...
(Date:8/26/2015)... ... August 26, 2015 , ... MediVet Biologics, a ... US laboratory is to open in Manhattan, Kansas in early October, 2015. The ... growth of research and development through collaboration with researchers from Kansas State University’s ...
(Date:8/26/2015)... Aug. 26, 2015  Roka Bioscience, Inc. (NASDAQ: ... advanced testing solutions for the detection of foodborne pathogens, ... at the Sidoti & Company Emerging Growth Conference on ... held at the New York Marriott Marquis. ... available through the investor relations section of Roka Bioscience,s ...
Breaking Biology Technology:iLab Solutions Named to 2015 Inc. 5000 List 2iLab Solutions Named to 2015 Inc. 5000 List 3Marken Ensures Safe Transportation Of Select Agents And Toxins 2MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 2MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 3
... Enroll in Phase 4 Study Initiated Pre-Registration,-, ... of Wyeth (NYSE: WYE ), today announced ... in Adults a major study in,adults of an ... pneumonia -- the leading cause of bacterial pneumonia,in ...
... Sept. 23 ,Monogram Biosciences, Inc. (Nasdaq: MGRM ... in collaboration with the Dana-Farber Cancer Institute,(DFCI), to ... cancer., In the study, Monogram,s proprietary HERmark ... samples from patients with breast cancer,approximately half of ...
... OSLO, September 23 Affitech AS, the ... it has accomplished the,second milestone in its ... fully human recombinant antibodies against an unnamed ... (Molecule Based Antibody,Screening) system that included its ...
Cached Biology Technology:Major Adult Vaccine Clinical Trial for Pneumonia Prevention Begins 2Major Adult Vaccine Clinical Trial for Pneumonia Prevention Begins 3Major Adult Vaccine Clinical Trial for Pneumonia Prevention Begins 4Major Adult Vaccine Clinical Trial for Pneumonia Prevention Begins 5Monogram and Dana-Farber Cancer Institute Initiate Evaluation of HERmark(TM) Breast Cancer Assay in Metastatic Breast Cancer 2Monogram and Dana-Farber Cancer Institute Initiate Evaluation of HERmark(TM) Breast Cancer Assay in Metastatic Breast Cancer 3Monogram and Dana-Farber Cancer Institute Initiate Evaluation of HERmark(TM) Breast Cancer Assay in Metastatic Breast Cancer 4Affitech Announces Second Milestone in Roche Antibody Discovery Collaboration 2
(Date:8/6/2015)... , August 6, 2015 ... (SMI) shows the world,s first Eye Tracking Integration ... Moverio BT-200 see-through head mounted display and on SMI,s ... quality and efficiency is brought to personalized visualization and ... first time, professionals and researchers can integrate gaze, and ...
(Date:8/5/2015)... MOUNTAIN VIEW, Calif. , Aug. 5, 2015 /PRNewswire/ ... it exhibits continuous growth in applications, penetration into newer ... year after year. The global biosensors space has seen ... having exited the market so far. (Photo ... from Frost & Sullivan, Analysis of the Global ...
(Date:7/31/2015)... , Kina, 31. juli 2015 Den 10. ... afholdt af BGI fra den 22. - 25. oktober i ... Konferencen fejrer sin 10-års fødselsdag i år. Siden starten ... indflydelsesrige årlige møder på ,omik,-feltet, og er en af ... ICG-10 fokuserer på nylige gennembrud og fremskridt ...
Breaking Biology News(10 mins):SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 3Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2
... NAIVASHA, KENYA (16 SEPTEMBER 2013)Kenyan farmers and agriculture ... shift in maize production as climate change threatens ... less productive for cultivation while simultaneously making others ... by the International Food Policy Research Institute (IFPRI) ...
... for producing the building blocks of life, amino acids, in ... The team from Imperial College London, the University ... when icy comets collide into a planet, amino acids can ... a rocky meteorite crashes into a planet with an icy ...
... Kashin-Beck disease (KBD) and Keshan disease (KD) are major ... under the guidance of Professor Xiong Guo from the ... Health, Medicine College of Xi,an Jiaotong University, Key Laboratory ... Education, Key Laboratory of Trace Elements and Endemic Diseases ...
Cached Biology News:Report: Climate change to shift Kenya's breadbaskets 2Report: Climate change to shift Kenya's breadbaskets 3Report: Climate change to shift Kenya's breadbaskets 4Scientists discover cosmic factory for making building blocks of life 2Several common differentially expressed genes between Kashin-Beck disease and Keshan disease 2Several common differentially expressed genes between Kashin-Beck disease and Keshan disease 3
... a cocktail of 3 siRNAs specifically targeted ... most popular product. The siTrio reagent guarantees ... your target gene when used under standard ... confirmation of optimal transfection with one of ...
... A multi-purpose, high gel-strength agarose suitable for ... from conventional constant field to Pulsed Field ... gel strength and exclusion limits, Multi ABgarose ... reduced running times. This in turn means ...
... molecular screening, low melting point agarose where ... is recommended for separation of nucleic acids ... PCR products. Micro ABgarose is also suited ... for blotting techniques. At a 3% concentration, ...
Sheep polyclonal to Salmonella Shoreditch ( Abpromise for all tested applications). Antigen: Native Salmonella shoreditch (Group D2)....
Biology Products: